Waverunner
Senior Member
- Messages
- 1,079
Great article by Derek Lowe.
http://pipeline.corante.com/archives/2014/02/03/the_return_of_gene_therapy_and_more.php
The advent of such techniques as CRISPR has people thinking again about gene therapy, and no wonder. This has always been a dream of molecular medicine - you could wipe all sorts of rare diseases off the board by going in and fixing their known genetic defects.
...
A less disturbing route might be to see if the technique can be used to gene-edit the egg and sperm cells before fertilization. Then you've got the possibility of editing germ cell lines in vivo, which really would wipe these diseases out of humanity (except for random mutations), but that will be another one of those hold-your-breath steps, I'd think. It's only a short step from fixing what's wrong to enhancing what's already there - it all depends on where you slide the scale to define "wrong". More fast-twitch muscle fibers, maybe? Restore the ability to make your own vitamin C? Switch the kid's lipoproteins to ApoA1 Milano?
For a real look into the future, combine this with last week's startling report of the generation of stem cells by applying stress to normal tissue samples. This work seems quite solid, and there are apparently anecdotal reports (see the end of this transcript) of some of it being reproduced already. If so, we would appear to be vaulting into a new world of tissue engineering, or at least a new world of being able to find out what's really hard about tissue engineering. ("Just think - horrible, head-scratching experimental tangles that were previously beyond our reach can finally be. . .")
Now have a look at this news about a startup called Editas. They're not saying what techniques they're going to use (my guess is some proprietary variant of CRISPR). But whatever they have, they're going for the brass ring:
(Editas has) ambitious plans to create an entirely new class of drugs based on what it calls “gene editing.” The idea is similar, yet different, from gene therapy: Editas’ goal is to essentially target disorders caused by a singular genetic defect, and using a proprietary in-house technology, create a drug that can “edit” out the abnormality so that it becomes a normal, functional gene—potentially, in a single treatment. . .
. . .Editas, in theory, could use this system to create a drug that could cure any number of genetic diseases via a one-time fix, and be more flexible than gene therapy or other techniques used to cure a disease on the genetic level. But even so, the challenges, just like gene therapy, are significant. Editas has to figure out a way to safely and effectively deliver a gene-editing drug into the body, something Bitterman acknowledges is one of the big hills the company has to climb.
...
http://pipeline.corante.com/archives/2014/02/03/the_return_of_gene_therapy_and_more.php
The advent of such techniques as CRISPR has people thinking again about gene therapy, and no wonder. This has always been a dream of molecular medicine - you could wipe all sorts of rare diseases off the board by going in and fixing their known genetic defects.
...
A less disturbing route might be to see if the technique can be used to gene-edit the egg and sperm cells before fertilization. Then you've got the possibility of editing germ cell lines in vivo, which really would wipe these diseases out of humanity (except for random mutations), but that will be another one of those hold-your-breath steps, I'd think. It's only a short step from fixing what's wrong to enhancing what's already there - it all depends on where you slide the scale to define "wrong". More fast-twitch muscle fibers, maybe? Restore the ability to make your own vitamin C? Switch the kid's lipoproteins to ApoA1 Milano?
For a real look into the future, combine this with last week's startling report of the generation of stem cells by applying stress to normal tissue samples. This work seems quite solid, and there are apparently anecdotal reports (see the end of this transcript) of some of it being reproduced already. If so, we would appear to be vaulting into a new world of tissue engineering, or at least a new world of being able to find out what's really hard about tissue engineering. ("Just think - horrible, head-scratching experimental tangles that were previously beyond our reach can finally be. . .")
Now have a look at this news about a startup called Editas. They're not saying what techniques they're going to use (my guess is some proprietary variant of CRISPR). But whatever they have, they're going for the brass ring:
(Editas has) ambitious plans to create an entirely new class of drugs based on what it calls “gene editing.” The idea is similar, yet different, from gene therapy: Editas’ goal is to essentially target disorders caused by a singular genetic defect, and using a proprietary in-house technology, create a drug that can “edit” out the abnormality so that it becomes a normal, functional gene—potentially, in a single treatment. . .
. . .Editas, in theory, could use this system to create a drug that could cure any number of genetic diseases via a one-time fix, and be more flexible than gene therapy or other techniques used to cure a disease on the genetic level. But even so, the challenges, just like gene therapy, are significant. Editas has to figure out a way to safely and effectively deliver a gene-editing drug into the body, something Bitterman acknowledges is one of the big hills the company has to climb.
...